Edgewise Therapeutics
Zhou Jiang has a background in pharmacy with a Pharm D. degree from Rutgers University. Jiang has extensive experience in the pharmaceutical industry, holding various roles such as Vice President of Early Commercial and Corporate Strategy at Edgewise Therapeutics, Senior Director Global Strategy Lead at UCB, and Director at Vertex Pharmaceuticals and Alexion Pharmaceuticals. Jiang has expertise in product management, marketing, and global strategy across different therapeutic areas. Additionally, Jiang also holds an MBA from NYU Stern School of Business.
This person is not in any teams
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.